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The TRPV1 receptor is associated with preferential stress in large
dorsal root ganglion neurons in early diabetic sensory neuropathy
Shuangsong Hong, Laura Agresta, Chunfang Guo and John W. Wiley
Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA
Diabetic neuropathy is one of the most frequent long-term
complications of diabetes mellitus and is a significant cause
of morbidity and mortality in diabetic patients. The most
common peripheral neuropathy is sensory, in which patients
can experience pain in the early to mid-phases of the disease
process that progresses to diminution of pain, position, and
vibratory sensation overtime (Boulton and Malik 1998;
Leinninger et al. 2004). Like other neuropathic pain states,
the pathogenesis of diabetic sensory neuropathy remains
poorly understood. Recently, increased oxidative stress has
been implicated in the onset and development of diabetes and
its late complications including neuropathy (Vincent et al.
2004b). In order to better understand the pathophysiology of
diabetic neuropathy, it will be important to determine the
cellular pathways that induce oxidative stress and cell injury
in sensory neurons in the early stages of the disease.
In the peripheral nervous system, the primary sensory
dorsal root ganglion (DRG) neurons with large cell bodies
(diameter > 35 lm) are typically associated with myelinated
A-b fibers and transmit proprioception and vibration sensa-
tion, whereas neurons with small cell bodies (diameter
< 25 lm) are typically associated with unmyelinated C-
fibers or thinly myelinated A-d fibers that are responsible for
conducting nociceptive stimuli (Lawson 2002). Diabetic
sensory neuropathy is conceptually considered a mixed
neuropathy involving both large and small, myelinated and
unmyelinated nerve fibers. Compared with these nerve fibers,
the soma of the primary afferent neurons is more vulnerable
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Abstract
Chronic diabetic neuropathy is associated with peripheral
demyelination and degeneration of nerve fibers. The mecha-
nism(s) underlying neuronal injury in diabetic sensory neu-
ropathy remain poorly understood. Recently, we reported
increased expression and function of transient receptor po-
tential vanilloid 1 (TRPV1) in large dorsal root ganglion (DRG)
neurons in diabetic sensory neuropathy. In this study, we
examined the effects of TRPV1 activation on cell injury path-
ways in this subpopulation of neurons in the streptozotocin-
induced diabetic rat model. Large DRG neurons from diabetic
(6–8 weeks) rats displayed increased oxidative stress and
activation of cell injury markers compared with healthy con-
trols. Capsaicin (CAP) treatment induced decreased labeling
of MitoTracker Red and increased cytosolic cytochrome c and
activation of caspase 3 in large neurons isolated from diabetic
rats. CAP treatment also induced oxidative stress in large
diabetic DRG neurons, which was blocked by pre-treatment
with caspase or calpain inhibitor. In addition, both l-calpain
expression and calpain activity were significantly increased in
DRG neurons from diabetic rats after CAP treatment. Treat-
ment with capsazepine, a competitive TRPV1 antagonist,
markedly reduced these abnormalities in vitro and prevented
activation of cell injury in large DRG neurons in diabetic rats
in vivo. These results suggest that activation of the TRPV1
receptor activates pathways associated with caspase-
dependent and calpain-dependent stress in large DRG neu-
rons in STZ-diabetic rats. Activation of the TRPV1 receptor
may contribute to preferential neuronal stress in large DRG
neurons relatively early in diabetic sensory neuropathy.
Keywords: calpain, diabetic neuropathy, dorsal root gan-
glion, neuronal injury, rat, transient receptor potential vanil-
loid 1.
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to damage under physiological stress or tissue injury because
of the absence of a blood barrier (McHugh and McHugh
2004). Several reports have demonstrated neuronal apoptosis
in streptozotocin (STZ)-induced diabetic rats or in cultured
DRG neurons harvested from diabetic rats (Russell et al.
1999; Zochodne et al. 2001; Schmeichel et al. 2003). Thus,
DRG neurons are a primary target of neural complications
and may be preferentially affected in diabetic sensory
neuropathy.
The transient receptor potential vanilloid 1 (TRPV1) is
highly expressed in DRG neurons. TRPV1 is a Ca2+-
permeable, non-selective cation channel, gated by noxious
heat, low pH, capsaicin (CAP), and endogenous ligands
(Caterina et al. 1997). Physiologically, TRPV1 is essential in
modulation of pain sensation and development of thermal
hypersensitivity following tissue injury or inflammation
(Caterina et al. 2000; Davis et al. 2000). Repeated activation
of the TRPV1 receptor causes the overload of intracellular
Ca2+, resulting in oxidative stress and apoptotic cell injury
(Shin et al. 2003; Kim et al. 2005). A recent report suggests
that activation of TRPV1 contributes to pancreatic beta cell
stress and may play a role in the pathogenesis of diabetes
mellitus (Razavi et al. 2006). Increased expression and
function of the TRPV1 receptor has been reported in large
DRG neurons in the STZ-induced diabetic rats (Hong and
Wiley 2005).
Based on these observations, we examined the hypothesis
that increased expression of the TRPV1 receptor in large
DRG neurons is associated with enhanced oxidative stress
and activation of cell injury pathways relatively early in the
natural history of diabetic sensory neuropathy. Markers of
oxidative stress and cellular injury were examined both
in vitro and in vivo in STZ-induced diabetic and control rats
in the absence or presence of the competitive TRPV1
receptor antagonist capsazepine (CZP). We observed that
increased expression of the TRPV1 receptor in large DRG
neurons in diabetic rats (diabetic for 6–8 weeks) was
associated with activation of oxidative stress and neuronal
injury which was prevented by treatment with CZP.
Materials and methods
Experimental animals
Male Sprague–Dawley rats were housed in the animal facility that
was maintained at 22C with an automatic 12 h light/dark cycle.
Diabetes mellitus was induced by a single intraperitoneal injection
of STZ at a dose of 45 mg/kg body weight to rats weighing 200–
220 g. Age-matched control rats received injections of saline
vehicle. Blood glucose levels greater than 300 mg/dL (16.7 mM)
3 days after STZ injection were considered diabetic. Rats meeting
this criterion were used experimentally 6–8 weeks after induction of
diabetes. All experiments were approved by the University of
Michigan Committee on Use and Care of Animals according to
National Institutes of Health guidelines.
Isolation of DRG neurons
The lumbar DRGs (L1-L6) were incubated at 37C in 0.3%
collagenase (Worthington type 2, Calbiochem, San Diego, CA,
USA) in minimal essential medium (Gibco, Carlsbad, CA, USA)
supplemented with 16.5 mM NaHCO3 and 28.2 mM glucose
minimal essential medium for 50 min and then in 0.1% trypsin
(type 1; Sigma, St. Louis, MO, USA) for 10 min. After titration in
minimal essential medium containing 10% fetal bovine serum, cells
were plated on cover glasses that were previously coated with calf
collagen. Isolated neurons from control or diabetic rat (n = 8 rats in
each group) were incubated in 95% air + 5% CO2 at 37C prior to
treatment with CAP (1 lM) for 4 h.
Administration of capsazepine in vivo and in vitro
TRPV1 antagonist CZP (30 mg/kg; Sigma) was administered either
intraperitoneally or by hind-paw injection in 20% dimethyl
sulfoxide/1% ethanol/1% Tween 80/78% saline in a volume of
0.2 mL right after STZ-injected rats develop high levels of blood
glucose (> 300 mg/dL) as described previously (Walker et al.
2003). Some STZ-injected rats were administered vehicle alone as
controls. The CZP was administered weekly after the first
subcutaneous application to sustain the effects in vivo. For
experiments using acutely dissociated DRG neurons, the plated
cells were treated with CAP (1 lM) for 4 h in the presence or
absence of TRPV1 antagonist CZP (10 lM), calpain inhibitor I
(50 lM; Santa Cruz Biotech, Santa Cruz, CA, USA), pan caspase
inhibitor Z-VAD-fmk (100 lM; Santa Cruz Biotech), or reactive
oxygen species-specific inhibitor N-acetyl-L-cysteine (NAC,
200 lM; Sigma).
Measurement of reactive oxygen species
Oxidative stress was measured by analyzing dihydroethidium
(DHE) oxidation to Eth (Russell et al. 2002) and immunofluores-
cence for 8-hydroxy-2¢-deoxyguanosine (8-OHdG), an oxidized
nucleoside of DNA (Schmeichel et al. 2003). Isolated DRG neurons
were incubated with 2 lM DHE (Molecular Probes, Eugene, OR,
USA) for 30 min at 37C, rinsed and then immediately viewed
under a microscope.
Staining cells with CMXRos
MitoTracker Red CMXRos staining (Molecular Probes, Carlsbad,
CA, USA) was performed to monitor the transmembrane potential
of mitochondria using the method described previously (Shibayama-
Imazu et al. 2006). After treatment with CAP, DRG neurons were
incubated with MitoTracker Red CMXRos (0.25 lg/mL; Molecular
Probes) and then cells were incubated for a further 15 min at 37C.
After several washes with culture medium, cells were fixed in 4% p-
formaldehyde in 0.1 M phosphate buffer, pH 7.4, and mounted on a
glass slide.
Calpain and caspase activity assay
Calpain activity was assayed spectrophotometrically using the
calpain-specific membrane-permeable peptide substrate Suc-LLVY-
7-amino-4-methylcoumarin (AMC) as previously described
(Liu-Snyder et al. 2006). Briefly, isolated DRG neurons from
control and diabetic rats were incubated with 130 lM of the calpain
substrate for 1 h at 37C. Then, neuron pellets were collected by
centrifugation at 1000 g and re-suspended in phosphate-buffered
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saline and transferred to 100 lL quartz cuvettes. Activity was
measured under linear conditions as a function of AMC hydrolysis
using excitation and emission wavelengths of 355 and 444 nm,
respectively. Caspase 3 like activity was measured in lysates of
DRG neurons using substrates N-acetyl-Asp-Glu-Val-Asp-7-amino-
4-methylcoumarin as described (Lau et al. 2006). Sample fluores-
cence was quantified at 355 nm excitation and 460 nm emission.
Mitochondria and cytosolic fraction preparation
Dorsal root ganglion mitochondria was isolated using a method
described (Kaur et al. 2007). Lumbar DRGs were collected and
homogenized with five volumes of ice-cold isolation buffer (20 mM
HEPES-KOH, pH 7.5, 215 mM mannitol, 75 mM sucrose,
10 mM KCl, 1.5 mM NaCl, 1.5 mM MgCl2, 1 mM sodium EDTA,
1 mM sodium EGTA, 1 mM dithiothreitol, and 0.1 mM phenyl-
methylsulfonyl fluoride). The tissue homogenate was spun at 1000 g
for 10 min in an Eppendorf microcentrifuge at 4C. The pellet was
re-suspended in isolation buffer and spun again at 14 000 g for
20 min in order to pellet the mitochondria. Both the pellet and
supernatant were collected for western blot analysis of cytochrome c.
Immunohistochemistry
Lumbar DRGs were removed and fixed for 2–3 h in 4% p-
formaldehyde in 0.1 Mphosphate buffer. Transverse sections through
the DRG (10 lm)were cut on a cryostat. Sections were permeabilized
with 0.3% Triton X-100 and blocked with 10% normal goat serum
overnight. In some experiments, isolated DRG neurons plated on
coated cover glasses were fixed and subjected to immunostaining.
Primary antibodies used were monoclonal anti-NF200 (N52 clone),
anti-cytochrome c (Sigma), anti-peripherin (Chemicon, Temecula,
CA, USA); polyclonal anti-caspase 3 (Cell Signaling, Danvers, MA,
USA), anti-8-OHdG (Genox Corp., Baltimore, MD, USA), and anti-
TRPV1, anti-caspase-activated DNase, anti-l-calpain (Santa Cruz
Biotech). Secondary antibodies Alexa Fluor 350, 488, and 594 from
Molecular Probes were used with 2-h incubation. Images were
acquired using a Zeiss Axioplan microscope or a Zeiss LSM510
confocal microscope (Zeiss, Thornwood, CA, USA) in the Micro-
scopy and Image Analysis Laboratory at the University of Michigan.
Western blot analysis
Lumbar DRGs were isolated and homogenized in ice-cold lysis
buffer containing 50 mM Tris, pH 8.0, 150 mMNaCl, 1 mM EGTA,
50 mM NaF, 1.5 mM MgCl2, 10% v/v glycerol, 1% v/v Triton
X-100, 1 mM phenylmethylsulfonyl fluoride, 1 mM Na3VO4, and
‘Complete’ protease inhibitor mixture (Roche Diagnostics, Basel,
Switzerland). Proteins were separated on 8% Tris–HCl gels and
transblotted to polyvinylidene difluoride membranes (Amersham
Biosciences, Piscataway, NJ, USA). The membranes were blocked
with 10% drymilk for 12 h and incubated with the primary antibodies
at 4C, overnight. The membranes were then incubated with
horseradish peroxidase-conjugated secondary antibodies (Amersham
Biosciences) for 1 h at 25C and developed using the West Dura
Supersignal chemiluminescence kit (Pierce, Rockford, IL, USA).
Data analysis
In each rat, 1500–2000 total DRG neurons were counted blindly.
Neurons were judged to be positive if they had mean brightness
values greater than the corresponding control background value
stained with the secondary antibody alone. The area of individual
neurons was determined by tracing the cell margins on a computer
screen. According to the measured area, neurons were classified as
large with cell area larger than 1200 lm2. The mean staining
intensity was determined by National Institute of Health IMAGE-J
software for each cell body by subtraction of the control background
staining and was normalized to cell area (100 lm2). Statistical
analyses were performed using non-parametric Mann–Whitney test
by GRAPHPAD INSTAT 3 (GraphPad Software Inc., San Diego, CA,
USA). Differences with p < 0.05 were considered significant.
Results
Diabetes was associated with activation of
caspase-dependent cell injury in DRG neurons in vivo
After STZ injection for 72 h, 75% of the rats developed high
levels of blood glucose (mean level = 482 ± 32 mg/dL),
whereas the control rats receiving vehicles had normal levels
(mean level = 92 ± 10 mg/dL). In diabetic rats (diabetic for
6–8 weeks), the number of activated/cleaved caspase 3
immunoreactivity (IR)-positive DRG neurons increased sig-
nificantly in situ compared with controls and these apoptotic
cells colocalized with the TRPV1 receptor, whereas the
number of caspase 3 IR-positive neurons was not altered in
TRPV1 IR-negative large neurons (Fig. 1a–c). Immunoblot
assays showed an increased level of the caspase-activated
DNase, a cytosolic nuclease responsible for oligonucleoso-
mal DNA fragmentation at the late stage of apoptosis, in
DRGs of diabetic rats (Fig. 1d and e), suggesting an
increased apoptotic neuronal injury as a result of diabetes.
It has been reported that the preferential derangement of
cytoskeletal neurofilament 200 (NF200), a major determinant
of large myelinated fibers, is an early morphological feature of
tissue injury (Posmantur et al. 1996). As shown in Fig. 1f and
g, diabetes was associated with a significant decrease in the
percentage of large NF200 IR-positive but not small periph-
erin IR-positive neurons in DRGs compared with controls.
Immunoblot assays also revealed a decrease in the protein
level of NF200 in DRGs in diabetic rats (Fig. 1d). These data
suggest that cytoskeletal NF200 was altered in diabetic DRGs
and support the interpretation that early diabetes may involve
preferential injury to this subpopulation of DRG neurons.
TRPV1 was associated with an increase in oxidative stress
in diabetic rats
We reported previously that the TRPV1 (vanilloid receptor 1)
expression was differentially increased in large DRG neurons
in diabetic rats compared with healthy controls by immuno-
histochemistry studies (Hong and Wiley 2005). In TRPV1
IR-positive neurons, the neurons also IR-positive for NF200
(large neurons) was 23.8 ± 1.5% in diabetic rats and
11.7 ± 2.3% in control rats, respectively (p < 0.05). In this
study, we examined whether TRPV1 activation could induce
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the accumulation of reactive oxygen species in this subpop-
ulation of neurons in diabetes in vitro. As shown in Fig. 2a
and b, the labeling intensity of 8-OHdG in large DRG
neurons (cell area > 1200 lm2) was significant higher in
diabetic rats compared with controls. CAP treatment, which
activates the TRPV1 receptor, induced a significant increase
in the labeling intensity of 8-OHdG in large DRG neurons
isolated from diabetic rats compared with the untreated as
measured by confocal microscopy imaging (p < 0.05), while
CAP treatment caused a modest increase in 8-OHdG
intensity in large neurons from controls (p = 0.07). TRPV1
antagonist CZP pre-treatment prevented the induction of 8-
OHdG in diabetic DRG neurons (Fig. 2b). Consistent with
this, the percentage of DHE-positive neurons also increased
significantly in DRGs in diabetic rats compared with
controls. After CAP treatment, the percentage of DHE-
positive neurons was significantly increased and this increase
was prevented by pre-treatment with CZP, calpain inhibitor I
or pan caspase inhibitor Z-VAD-fmk (Fig. 2c). After CAP
treatment, the number of DHE-positive neurons was
increased to 39.4 ± 4.6% from 18.9 ± 2.1% in diabetic rats
(p < 0.05), while this percentage significantly decreased to
20.9 ± 1.4% after CZP pre-treatment, to 20.6 ± 3.3% after
calpain inhibitor I pre-treatment, or to 18.7 ± 1.7% after pan
caspase inhibitor pre-treatment. Incubation with TRPV1
antagonist CZP alone without CAP did not affect the number
of DHE-positive neurons compared with the untreated. In
addition, to investigate CAP-induced oxidative stress in
DRG neurons, the reactive oxygen species-specific inhibitor
NAC (200 lM) was pre-incubated with acutely dissociated
DRG neurons before CAP treatment. NAC pre-treatment
significantly reduced the number of DHE-positive neurons
compared with CAP-treated diabetic neurons (p < 0.05;
Fig. 2c). To confirm the presence of increased oxidative
stress in DRG neurons in diabetic rats in situ, DRG sections
from diabetic rats were subjected to 8-OHdG staining and
colocalized with TRPV1 (Fig. 2d). The percentage of DRG
neurons IR-positive for both 8-OHdG and TRPV1 increased
significantly in diabetes compared with controls (Fig. 2d). In
addition, the percentage of neurons IR-positive for both 8-
OHdG and NF200 was significantly increased in DRGs from
diabetic rats, suggesting the oxidative stress is preferentially
increased in large, NF200 IR-positive neurons in early
diabetic rats (Fig. 2e).
Capsaicin-induced collapse of mitochondrial
transmembrane potential and activation
of caspase-dependent cell injury in DRG neurons
Mitochondrial transmembrane potential was evaluated by
staining DRG neurons with MitoTracker Red CMXRos, a
lipophilic cationic dye shown to rapidly accumulate in
normal mitochondria as a result of the negative transmem-
brane potential of the organelles (Shibayama-Imazu et al.





Fig. 1 DRG neurons from diabetic rats demonstrated an increase in
caspase-dependent cell injury. (a) Double immunofluorescence showed
an increase in cleaved caspase 3 labeling (green) in TRPV1 IR-positive
(red) DRG neurons in diabetic (DM) rats compared with controls (CT).
The neurons IR-positive for both caspase 3 and TRPV1 were indicated
by white arrows. (b) Confocal image of cultured DRG neurons that ex-
press TRPV1 receptor mainly at cell membrane. (c) Bar graph showed
an 85 ± 6% increase in the number of neurons that were IR-positive for
both TRPV1 and cleaved caspase 3 in TRPV1 IR-positive neurons in
diabetic rats (n = 5). (d and e) Immunoblot analysis of protein levels of
caspase-activated DNase (CAD), NF200, and peripherin in DRGs
(n = 4). (f) The large NF200 (blue, marker for large A-fiber neurons) IR-
positive neurons and small peripherin (marker for small C-fiber neurons)
IR-positive neurons did not colocalize in DRGs. (g) Bar graph showing
the percentage of DRG neurons IR-positive for NF200 or peripherin in
control and diabetic rats (n = 10). Scale bar: 40 lm. *p < 0.05.
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was significant lower in isolated large DRG neurons that
expressed the TRPV1 receptor in diabetic rats compared with
controls (50 TRPV1 IR-positive large neurons counted per
rat). CAP treatment caused a significant decrease in the
labeling intensity of MitoTracker Red CMXRos in large,
TRPV1-expressing DRG neurons from diabetic DRG neu-
rons but not controls. CZP pre-treatment prevented the
decrease in the mitochondrial membrane potential in large
DRG neurons isolated from diabetic rats. In contrast, the
MitoTracker Red CMXRos staining was not altered in DRG
neurons isolated from control rats after CAP treatment
compared with untreated neurons (Fig. 3a). We next exam-
ined the activation of caspase 3 in DRG neurons after CAP
treatment by immunofluorescence staining. In TRPV1 IR-
positive cells, the presence of cleaved/activated caspase 3
staining was significantly more intense in neurons after CAP
treatment in diabetic rats (Fig. 3b). We also examined
caspase activity in DRG neurons from control and diabetic
rats. Caspase activity was significantly increased in diabetic
rats compared with controls in isolated DRG neurons and in
CAP-treated DRG neurons (Fig. 3c). Moreover, the levels of
cytochrome c in DRG neurons after CAP treatment increased
significantly in DRG neurons from diabetic rats compared
with controls as shown by immunofluorescence staining
(Fig. 3d). Western blot analysis also showed that cytochrome
c was significantly increased in the cytosolic fraction of
DRGs from diabetic rats compared with controls (Fig. 3e and
f), consistent with the previous reports (Srinivasan et al.
2000; Di Noia et al. 2006).
Capsaicin treatment caused greater Ca2+-dependent cell
injury in DRG neurons in diabetic rats
Calpains, including widely expressed l-calpain, are Ca2+-
dependent neuronal cysteine proteases that are known to be
involved in the proteolysis of a number of important proteins
and plays a important role in neuronal cell death (Lankiewicz
et al. 2000). After CAP treatment, large DRG neurons that
were IR-positive for TRPV1 displayed a significant increase
in the labeling intensity of l-calpain in diabetic rats
compared with controls (Fig. 4a). To assess calpain activity,
DRGs from control and diabetic rats were treated with CAP
in the presence of calpain substrate Suc-LLVY-AMC. As
shown in Fig. 4b, CAP-activated Suc-LLVY-AMC hydroly-
sis was significantly increased in DRGs isolated from
diabetic rats compared with controls. Consistent with this,
CAP treatment also induced a significant increase in the level
of l-calpain protein in isolated DRG neurons from diabetic




Fig. 2 Oxidative stress was enhanced in large DRG neurons in dia-
betic rats. (a) Immunofluorescence staining showed increased labeling
intensity of 8-OHdG in large DRG neurons (cell diameter > 40 lm and
cell area > 1200 lm2) isolated from diabetic rats after capsaicin
treatment. The inset was a typical image of 8-OHdG staining viewed
under the confocol microscope. Scale bar: 100 lM. (b) Pixel intensity
measurement of 8-OHdG labeling showed that the increase in
8-OHdG staining was prevented in diabetic DRG neurons with pre-
treatment with TRPV1 antagonist capsazepine. (c) Capsaicin treat-
ment increased the percentage of DHE-positive DRG neurons isolated
from diabetic rats. Pretreatment with capsazepine, calpain inhibitor I,
pan caspase inhibitor or reactive oxygen species inhibitor N-acetyl-L-
cysteine (NAC) blocked the increased labeling of DHE evoked by
capsaicin in large DRG neurons from diabetic rats. (d) Double
immunofluorescence showing increased 8-OHdG labeling (green) in
TRPV1 IR-positive neurons (red) in situ in DRGs from diabetic rats.
Scale bar: 40 lm. (e) Bar graph showing the increased number of 8-
OHdG IR-positive neurons in large, TRPV1-expressing DRGs from
diabetic rats in situ. *p < 0.05.
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cytoskeletel NF200 was reduced after CAP treatment in
diabetic rat DRGs, suggesting the initiation of Ca2+-depen-
dent cell injury pathway in diabetic DRGs.
Capsazepine treatment, in vivo, prevented the reduction in
large NF200 IR-positive DRG neurons in diabetic rats
To investigate the effects of TRPV1-mediated neuronal
injury in situ, CZP was delivered to the rat hind paw and
intraperitoneally prior to and after STZ-injection. After
2 months of CZP treatment, DRGs from control and diabetic
rats were isolated and processed for staining with NF200 and
peripherin. No differences were observed between hind paw
and intraperitoneal injection and the data were pooled for
analysis. In diabetic rats not receiving CZP treatment, the
number of large-sized DRG neurons decreased significantly
as described above. In rats that received CZP treatment, the
percentage of large-sized, NF200 IR-positive DRG neurons
was not significantly different compared with healthy
controls. Treatment with CZP had no effect on the percentage
of neurons in control rats (Fig. 5a). The percentage of small
DRG neurons, as measured by peripherin immunofluores-






Fig. 3 Capsaicin treatment induced shift of mitochondrial transmem-
brane potential and increased cell injury in DRG neurons isolated from
diabetic rats. (a) Bar graph depicting the changes in the labeling
intensity of MitoTracker Red in DRG neurons treated with capsaicin
and/or capsazepine in diabetic rats (n = 5). (b) Cleaved caspase 3
was activated and increased in DRG neurons from diabetic rats after
capsaicin treatment. (c) Bar graph showing increased caspase activity
in DRG preparations from diabetic rats when compared with controls
before and after capsaicin treatment (n = 4). (d) Increased cytochrome
c labeling in DRG neurons IR-positive for TRPV1 in diabetic rats after
capsaicin treatment. Scale bar: 40 lm. (e) Western blot analysis of the
expression level of cytochrome c in crude mitochondria and cytosol
fraction in DRGs from control and diabetic rats. (f) Pixel graph showing
cytochrome c was significantly increased in the cytosolic fraction of
DRGs from diabetic rats compared with controls. The cytochrome c
band density was normalized to b-actin. *p < 0.05, **p < 0.01.
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control and diabetic rats (Fig. 5b). These data provide
additional support that activation of the TRPV1 receptor-
ion channel complex contributes to neuronal injury in early
diabetes.
Discussion
Oxidative stress and programmed cell death have been
proposed to play a role in the natural history of diabetic
neuropathy (Russell et al. 1999; Srinivasan et al. 2000;
Cheng and Zochodne 2003; Schmeichel et al. 2003; Vincent
et al. 2004a,b). However, our understanding of the mecha-
nisms underlying neuronal injury in diabetic sensory neu-
ropathy is incomplete. We believe that this is the first report
demonstrating activation of TRPV1 receptor induces prefer-
ential activation of oxidative stress and neuronal injury
pathways in large DRG neurons at a relatively early stage of
diabetes. In diabetic rats (diabetic for 6–8 weeks), oxidative
stress and cell injury markers were significantly increased
in vivo in large NF200 IR-positive DRG neurons that express
TRPV1. CAP-evoked TRPV1 activation resulted in loss of
the mitochondrial membrane potential, accumulation of
reactive oxygen species, and induction of both apoptotic
and calpain-dependent cell injury in DRG neurons from
diabetic rats. The competitive TRPV1 receptor antagonist
CZP inhibited these effects in vitro and markedly reduced
activation of cell injury mechanisms in large DRG neurons in
diabetic rats in vivo.
TRPV1 is a ligand-gated non-selective cation channel and
its activation leads to Ca2+ influx and membrane depolari-
zation (Caterina et al. 1997; Shin et al. 2003). Enhanced
activity of TRPV1 is known to place neurons at increased
risk for stimulation of calpain (calcium)-dependent neuronal
injury. Although TRPV1-mediated cell death has been
reported in a variety of cell types (Jambrina et al. 2003;
Shin et al. 2003; Kim et al. 2005), the majority of these
investigations employ either malignant or transformed cells
and the role of TRPV1 has not been examined in diabetic
sensory neuropathy. It is interesting that TRPV1-mediated
neuroprotection against excitotoxicity that is attributed to the
endogenous desensitization of TRPV1 has been reported
recently in the brain (Veldhuis et al. 2003). However, our
previous study demonstrates that TRPV1 desensitization is




Fig. 4 Increased Ca2+-dependent protease, l-calpain, in DRGs from
diabetic rats. (a) Double immunofluorescence staining showed in-
creased l-calpain labeling in TRPV1 IR-positive neurons after cap-
saicin treatment. Scale bar: 40 lm. (b) Increased calpain activity in
DRG neurons isolated from diabetic rats after capsaicin treatment.
(c and d) Increased level of l-calpain and decreased level of NF200 in
DRGs in diabetic rats after capsaicin treatment (n = 4). *p < 0.05.
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TRPV1 by CAP triggers an increase in TRPV1 currents with
a longer duration compared with controls (Hong and Wiley
2005). Alternatively, the endogenous level of TRPV1
agonists might be increased in diabetes to activate more
TRPV1 channels open and Ca2+ influx. For example, the
endogenous CB1 agonist cannabinoid anandamide, which
also activates TRPV1, was increased in diabetes (Bloomgar-
den 2006). Moreover, our previous and current studies show
that the expression of TRPV1 increased significantly in large
myelinated A-b fiber (NF200 IR-positive) DRG neurons in
diabetic rats (Hong and Wiley 2005), possibly acting as
modulators to transmit pain signals or maintain the peripheral
and central sensitization in neuropathy states. This is
consistent with the recent findings that TRPV1 expression
increases in DRG neurons in other neuropathic pain models
like nerve injury and that silencing TRPV1 reduces neuro-
pathic pain (Christoph et al. 2006; Biggs et al. 2007). In the
current study, we report that activation of TRPV1 by CAP
induces oxidative stress and activation of apoptotic cascade
in large TRPV1-expressing DRG neurons from diabetic rats,
which was inhibited by calpain inhibitor, caspase inhibitor
and reactive oxygen species-specific inhibitor. Treatment
with the TRPV1 antagonist CZP reduced CAP-induced cell
cytotoxicity in diabetic DRG neurons in vitro and prevented
the reduction in NF200-immunoreactive large DRG neurons
in vivo. These observations are in agreement with a
neuroprotective role for the TRPV1 antagonist CZP reported
previously (Veldhuis et al. 2003; Kim et al. 2005). Our
findings may have pathophysiological significance and
support a mechanistic role for the TRPV1 receptor in
diabetic sensory neuropathy.
A substantial body of research supports that mitochondria
undergo structural and functional changes that contribute to
activation of cell injury pathways. Reduction of mitochondrial
transmembrane potential is an early step of programmed cell
death. Our data support the concept that the development of
neuronal injury in DRGs in diabetes occurs, at least in part,
through the alterations of mitochondria following activation of
TRPV1 receptor. Specifically, the mitochondrial transmem-
brane potential was preferentially depolarized in large DRG
neurons expressing TRPV1 after CAP treatment in diabetic
rats, which may be related to an overload of intracellular Ca2+
that depolarizes the mitochondrial transmembrane potential
and eventually leads to the opening of mitochondrial perme-
ability transition (MPT) pores (Bernardi 1999). In addition, the
elevation of intracellular Ca2+ also triggers the formation of
reactive oxygen species by uncoupling electron transport from
ATP production in mitochondria (Vincent et al. 2004a).
Although these free radical reactions are essential for host
defense mechanisms, the overproduction of free radicals may
cause tissue injury and programmed cell death (Pop-Busui
et al. 2006). Our data indicate that the increase in oxidative
stress as measured by 8-OHdG and DHE is associated with
TRPV1 activation because CAP-induced accumulation of
reactive oxygen species and the increase in caspase activity
were reversed by pre-treatment with the TRPV1 antagonist
CZP in these neurons. The release of cytochrome c was also
observed in large DRG neurons isolated in diabetic rats after
CAP treatment in vitro and in the cytosolic fraction of DRG
neurons in diabetes in situ. Consistent with our data, morpho-
logical changes such as mitochondrial swelling caused by
TRPV1 activation has been observed in sensory neurons
(Szoke et al.2002). Thus, it is likely that TRPV1-mediated cell
injury in diabetic sensory neuropathy involves accumulation
of reactive oxygen species and opening of MPT pores that
consequently leads to mitochondrial dysfunction, substantial
swelling of the mitochondria with rupturing outer membrane
and releasing apoptosis-inducing factors such as cytochrome c,
and subsequent activation of caspase 3.
In addition to the caspase-dependent cell injury pathway,
our data support a calpain-mediated cell injury pathway that
may be involved in diabetic peripheral neuropathy. Calpain, a
Ca2+-dependent cysteine protease, has been implicated in a
variety of disorders, including Parkinson’s disease, Alzhei-
(a)
(b)
Fig. 5 Capsazepine pretreatment prevented the decrease in large
NF200 IR-positive DRG neurons in diabetic rats in vivo. (a) Bar graph
showing the percentage of large NF200 IR-positive neurons in DRGs
in diabetic rats before and after capsazepine treatment (n = 6). (b) No
change in small, peripherin IR-positive neurons was observed in dia-
betic rats with or without capsazepine treatment. *p < 0.05.
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mer’s disease, multiple sclerosis, and spinal cord injury
(Harwood et al. 2005). We observed TRPV1-associated
elevation of calpain activity and l-calpain expression in
diabetic DRG neurons compared with controls. It is likely
that TRPV1 activation induces an increase in intracellular
calcium, activates Ca2+-activated calpain, and eventually
leads cell injury in diabetic DRG neurons. First, calpain can
cleave its specific substrates which can directly or indirectly
lead to cell rupture (Huang and Wang 2001). Second, calpain
may cleave important regulators of apoptosis such as
proapoptotic Bid and anti-apoptotic Bcl-XL (Nakagawa and
Yuan 2000; Mandic et al. 2002), suggesting a crosstalk
between the calpain-dependent and caspase-dependent cell
injury pathways (Raynaud and Marcilhac 2006). Conse-
quently, calpain-mediated hydrolysis of these proteins leads
to changes in their activity or intracellular localization. In
addition, activation of calpain in the large diabetic DRG
neurons may increase the permeability of plasma membrane
(Huang and Wang 2001), making it more susceptible to the
damage exerted by other factors, such as osmotic force.
Because calpain substrates represent some of the most
important cellular proteins including ion pumps and chan-
nels, structural proteins, and intracellular enzymes (Liu et al.
2004b), the TRPV1 receptor may represent an attractive
therapeutic target to regulate calpain activation and down-
stream events. A recent study suggests that expression of
calpain-10 is specifically activated in diabetes. Over-expres-
sion of calpain-10 resulted in mitochondrial dysfunction
through the cleavage of complex I of the electron transport
chain and activation of MPT (Arrington et al. 2006).
Additional studies are required to investigate whether
calpain-10 activation is also mediated by TRPV1 receptor
in diabetic sensory neuropathy.
Recent studies using morphometric analysis support the
provocative observation that diabetic peripheral neuropathy
may be associated with preferential loss of large DRG
neurons in long-term diabetic rats (Kishi et al. 2002). In
contrast, other studies using morphometric methods have not
observed loss of DRG neurons in the time frame of diabetes
(diabetic for 6–8 weeks) that we studied in the current
experiments (Zochodne et al. 2001; Cheng and Zochodne
2003). This suggests the intriguing possibility that activation
of oxidative stress and cell injury pathways relatively early in
diabetes is not irrevocably linked to concurrent loss of
neurons. It is possible that the apparent loss in large DRG
neurons may reflect the preferential effects of diabetes-
associated hyperosmolarity and concomitant shrinkage of the
soma in this subpopulation of neurons and, therefore, not
represent an actual dropout of DRG neurons. Although
shrinkage of large myelinated axons has been observed in
STZ-induced diabetes, the decrease of large, NF200 IR-
positive neurons observed in diabetic rats is not likely
attributable to cell shrinkage because the expression of
NF200 does not correlate with axonal caliber (Sayers et al.
2003). The decrease of NF200 in DRGs in early diabetic rats
(6–8 weeks) we observed is consistent with the previous
reports that also demonstrate a reduction of neurofilament
heavy chain in axons at early stages of diabetes possibly
because of reduced synthesis of transcripts (Mizisin et al.
1999; Sayers et al. 2003). In 2–3 months diabetic rats, the
neurofilament phosphorylation is triggered and thereafter
induces expression and accumulation of neurofilament in
DRGs (Sayers et al. 2003). Neurofilaments are important
cytoskeletal proteins that act together to form and maintain
cell shape and facilitate the transport of particles and
organelles within the cytoplasm (Liu et al. 2004a). Abnor-
malities of neurofilament synthesis and transport have been
suggested to contribute to the axonal atrophy and reduction
of nerve conduction velocity in diabetes (Scott et al. 1999;
Sayers et al. 2003). Furthermore, neurofilaments are a major
target in conditions of elevated oxidative stress (Leski et al.
2001). Increased oxidative stress may degrade the neurofil-
aments in large DRG neurons in diabetic rats. Activation of
calpain observed in these neurons can also cleave neurofil-
aments such as NF200 (Stys and Jiang 2002). The prefer-
ential cell stress observed in large NF200 IR-positive DRG
neurons in diabetes is consistent with a recent study that large
NF200 IR-positive neurons are more vulnerable compared
with small DRG neurons in response to injury (Guseva and
Chelyshev 2006). Thus, our data support that neuronal stress
does occur in large DRG neurons relatively early in diabetic
neuropathy at this time frame (diabetic for 6–8 weeks).
However, the cell injury does not translate into a parallel loss
of neurons. This suggests that primary neurons are relatively
‘protected’ from cell death (defined as loss or drop out of cell
bodies), either by the robust expression of cytoprotective
mechanisms or reduced expression of key regulatory com-
ponents of cell death, such as caspase 8.
In summary, our data suggest that increased expression
and activation of the TRPV1 receptor in the subpopulation of
large DRG neurons is associated with the activation of
oxidative stress and neuronal injury pathways at a relatively
early stage of diabetes.
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